Myo-inositol for PCOS: evidence, limits and metformin
What myo-inositol may help with in PCOS, how it compares with metformin, and why no dose, 40:1 ratio or fertility benefit is established.
Written and evidence-checked by the VeriNourish Editorial Team against 6 named sources listed below. No licensed clinician reviews this content.
Inositol has become the supplement most often suggested to women with PCOS, and the claims made for it stretch from steadier cycles to restored fertility. Some of that is supported. A good deal of it is not, and the gap between the two is where most of the money gets spent.
Here is what the trials show, where the evidence runs out, and how it compares with metformin, the medication it is usually pitched against. If the name is new to you, PCOS was officially renamed PMOS in May 2026, though almost everyone still says PCOS.
Does myo-inositol help PCOS?
What inositol is worth depends entirely on what you want from it.
| Your goal | Is inositol a reasonable choice? |
|---|---|
| More regular cycles | Possibly. Some trials found benefit, but methods and certainty vary |
| Lower testosterone or glucose measures | Possibly. Results differ by marker and review |
| Reducing excess hair growth | Metformin is preferred over inositol in the guideline |
| Getting pregnant | Evidence is uncertain; inositol is not recommended as a fertility therapy |
| Avoiding metformin's digestive side effects | Inositol is often better tolerated, but may offer less clinical benefit |
What inositol actually is
Inositol is a sugar alcohol your body makes and also gets from food. Two forms matter here: myo-inositol and D-chiro-inositol. Both are involved in insulin-signalling pathways, which is why they have been studied in a condition often associated with insulin resistance.
The mechanism makes the idea plausible. PCOS can involve insulin resistance and androgen excess, but the condition varies between women and a plausible mechanism does not show that a supplement improves the outcomes you care about (Diagnostics, 2023).
Plausible is not the same as proven, so the question is what happened when it was tested.
What the evidence supports
A 2023 meta-analysis pooled 26 randomized trials covering 1,691 women. Against placebo, it reported more cycle normalization, lower total and free testosterone, higher SHBG, and a small reduction in fasting glucose (Reproductive Biology and Endocrinology, 2023).
In that meta-analysis, fasting insulin and HOMA-IR did not show a clear improvement against placebo, nor did glucose measured across a tolerance test. Other reviews have produced different estimates, which is one reason the guideline describes the evidence as limited rather than treating inositol as a proven insulin-sensitising therapy.
The authors are also candid about the limits: small trials, heterogeneous definitions of what counts as a regular cycle, different doses, and moderate to high risk of bias in some domains. The systematic review prepared for the international PCOS guideline reached the more cautious conclusion: evidence for individual outcomes was limited and inconclusive, with very low certainty for many comparisons (J Clin Endocrinol Metab, 2024).
Inositol versus metformin
Four of those trials compared inositol with metformin directly. They were small, so the results help frame the choice but cannot establish that the two treatments are equivalent.
| Inositol | Metformin | |
|---|---|---|
| Cycle normalization | No clear difference detected in small trials | No clear difference detected in small trials |
| BMI, testosterone, fasting glucose, HOMA-IR | No clear difference detected for several outcomes | No clear difference detected for several outcomes |
| Excess hair growth | Weaker | Better |
| Side effects | 7% of users | 53% of users |
| Availability | Over the counter | Prescription |
The same meta-analysis reported fewer adverse events with inositol, with bloating, nausea and weakness contributing to the metformin figure (Reproductive Biology and Endocrinology, 2023). These were small trials, so a finding of no clear difference on an outcome should not be read as proof that the treatments are equivalent.
The 2023 international guideline reaches a compatible but more cautious verdict. It says inositol "could be considered" on the basis of limited harm and possible metabolic improvement, while noting limited clinical benefit for ovulation, hirsutism or weight, and it recommends metformin over inositol specifically for excess hair growth and central weight, while acknowledging metformin causes more digestive side effects (J Clin Endocrinol Metab, 2023).
Put those together and a practical rule falls out. If metformin works for you and you tolerate it, there is no strong reason to switch. If side effects are the reason you stopped taking it, inositol is a reasonable thing to raise with your doctor.
Fertility: where the evidence runs out
This is where marketing and evidence part company most sharply.
A Cochrane review examined 13 trials in 1,472 women with PCOS trying to conceive. Its conclusion on the outcome that matters was that it is uncertain whether myo-inositol improves live birth rates, with an odds ratio of 2.42 whose confidence interval runs from 0.75 to 7.83 (Cochrane, 2018). An interval that wide, crossing no effect, means the data cannot tell you whether it helps, does nothing, or something in between. Clinical pregnancy was equally uncertain. Every one of those findings was graded very low quality.
The guideline, by contrast, is unambiguous about what does work for ovulation: letrozole is the first-line treatment for ovulation induction in women with PCOS and no other fertility factor (J Clin Endocrinol Metab, 2023).
If you are trying to conceive, that is the conversation to have. Inositol is not a substitute for it, and buying it as a fertility treatment is buying something the evidence does not support.
The 40:1 ratio on the label
Most products sold for PCOS use a 40 to 1 ratio of myo-inositol to D-chiro-inositol, presented as the physiological or clinically proven combination, usually at a premium.
The guideline addresses this directly. Specific types, doses or combinations of inositol cannot currently be recommended in adults or adolescents with PCOS, because the quality of evidence is not there to support any of them (J Clin Endocrinol Metab, 2023).
The 40:1 ratio is a market convention that hardened into a selling point. It may turn out to be right. It has not been shown to be, and no guideline endorses it, so paying more for that number on the label is not something the research justifies.
Dose, and why we are not giving you one
Trials have used a range of doses, and the same guideline sentence that rules out recommending a combination also rules out recommending a dose. We are not going to invent a figure the evidence does not carry.
What that means in practice: if you and your doctor decide to try inositol, treat it as a supplement with uncertain dose standards, limited reported harms and no validated protocol. Agree in advance what outcome you are watching and when you will review it.
Whatever you take, it sits alongside the wider PCOS plan rather than replacing it. Regular meals with protein, fiber and lower-GI carbohydrates may suit some women, while the guideline recommends tailoring lifestyle support to your preferences and health goals.
Side effects and safety
Inositol caused fewer digestive side effects than metformin in the small head-to-head trials, but that is not the same as having strong long-term safety data. The international guideline notes that supplement dose, quality and combinations vary and advises women to tell their health professional when they take inositol (J Clin Endocrinol Metab, 2023).
Stop and ask for medical advice if a supplement causes persistent diarrhea, vomiting or other symptoms that do not settle. If you are pregnant, trying to conceive, taking glucose-lowering medication or considering replacing prescribed metformin, discuss the plan before changing treatment.
When to talk to your doctor
Raise it if you have PCOS and your cycles are irregular, if you stopped metformin because of side effects, or if you are considering inositol while trying to conceive. Fertility treatment deserves a direct discussion because the guideline treats inositol as experimental in that setting and recommends established ovulation-induction options instead.
Inositol is also not a reason to skip the checks that should follow a PCOS diagnosis. Our PCOS guide sets out the blood sugar, lipid, blood pressure and mental health screening the guideline asks for, and none of that changes because you started a supplement.
Frequently asked questions
Does inositol work for PCOS?
It may improve some metabolic or cycle measures, but the certainty is low and results vary by outcome. The 2023 international guideline notes possible metabolic improvement but limited clinical benefits for ovulation, excess hair growth or weight. Evidence for fertility outcomes remains uncertain.
Is inositol better than metformin?
The available small trials did not find clear differences for several outcomes, but that does not prove the treatments are equivalent. The 2023 international guideline prefers metformin for excess hair growth and central adiposity, while noting that metformin causes more digestive side effects.
Does inositol help you get pregnant with PCOS?
The honest answer is that nobody knows. A Cochrane review of 13 trials in 1,472 women concluded it is uncertain whether myo-inositol improves live birth rates, and rated the evidence very low quality. If pregnancy is your goal, the guideline first-line treatment for ovulation induction is letrozole, not a supplement.
Is the 40:1 myo-inositol to D-chiro-inositol ratio better?
There is no guideline support for it. The 2023 international guideline states plainly that specific types, doses or combinations of inositol cannot currently be recommended because the quality of evidence is not there. The 40:1 ratio is a marketing standard, not an evidence-based one, so paying extra for it is not justified by the research.
Is inositol safe?
Trials generally report fewer digestive side effects than metformin, but long-term safety data and adverse-event reporting are limited. Guidelines also warn that supplement dose, quality and combinations can vary. Tell your healthcare professional what you take, especially if you are trying to conceive.
References
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome · Journal of Clinical Endocrinology & Metabolism, 2023
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials · Reproductive Biology and Endocrinology, 2023
- Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines · Journal of Clinical Endocrinology & Metabolism, 2024
- Inositol for subfertile women with polycystic ovary syndrome · Cochrane Database of Systematic Reviews, 2018
- Polycystic ovary syndrome: pathophysiology and controversies in diagnosis · Diagnostics (Basel), 2023
- Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care · Endocrine Society, 2026